AMYLIN PHARMACEUTICALS IPO RAISES $56 MIL.
AMYLIN PHARMACEUTICALS IPO RAISES $56 MIL. on Jan. 17 with 4 mil. shares going for $14 per share. The offering increased substantially in size and price from the estimates in a Nov. 27 prospectus filed with the Securities & Exchange Commission. The prospectus estimated a price of $10 per share for 3 mil. shares. The offering, underwritten by Morgan Stanley and Alex. Brown, testifies to the continued interest in new biotech offerings despite a recent softening in the market for biotech shares. Proceeds will support San Diego-based Amylin's research and development efforts for diabetes and obesity based on the pancreatic hormone amylin, as well as other general corporate purposes. The company is ready to carry its R&D into human clinicals: the firm filed an IND on Dec. 10. Initial clinical trials will focus on the clinical pharmacology of amylin in replacement therapy applications. Future applications may include amylin blockade therapy for both diabetes and obesity, as well as possible amylin agonist use for treatment of osteoporosis, the company said. Amylin announced Jan. 6 that former Burroughs Wellcome researcher Robert Butz, PhD, has joined the company as vice president of development. Butz most recently served as VP-clinical operations for the international contract research organization Quintiles. At Amylin, Butz will be responsible for preclinical development, clinical R&D, clinical data management and project management. Amylin is working with Glaxo in the blockade therapy area under an agreement signed in October ("The Pink Sheet" Nov. 4, T&G-1). As part of the collaboration, each firm will assign 20 to 35 scientists to a joint effort to "develop amylin blockers for the treatment of adult onset diabetes," the prospectus says. In exchange for an upfront $2 mil. research fee, Glaxo has exclusive rights to commercialize any product candidates, while Amylin retains the right to copromote any marketable products on a product-by-product, market-by-market basis, "subject to reimbursing Glaxo for certain development costs." Glaxo has no equity stake in Amylin. Amylin retains all commercial rights to its amylin replacement therapy for diabetes indications and at present plans to undertake all clinicals, manufacturing and marketing, the prospectus notes. "The company plans to file additional INDs on amylin-based compounds for treating severe hypoglycemia in insulin-dependent diabetics, for reducing the risk of insulin-induced hypoglycemia, and for treating an underlying cause of adult onset diabetes," the prospectus adds.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth